You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa

    SBC: NANOVIR, LLC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The proposal seeks support for the pre-clinical development of broad spectrum compounds for treatment of human papillomavirus (HPV). HPV, the most common sexually-transmitted virus, is the cause of cervical dysplasia and cervical cancer. It has also been implicated in several other hyperproliferative diseases, such as cancers of the mouth and anus, as well as t ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Fluorescein for Sentinel Lymph Node Detection

    SBC: VESTAN INC            Topic: NCI

    DESCRIPTION (provided by applicant): In this Phase II STTR project, Vestan Medical Imaging, Inc. will complete the development and clinical evaluation of its proprietary formulation of a fluorescent drug and new medical devices for Sentinel Lymph Node (SLN) biopsy for the surgical treatment of melanoma and breast cancer. Vestan will partner with the University of Utah Huntsman Cancer Institute (HC ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Naloxone Nasal Spray Development

    SBC: ANTIOP, INC.            Topic: NIDA

    DESCRIPTION: The following proposal is a follow-on Phase 2 b application from our initial proposal (1-R42 DA 030001). U.S. drug overdose deaths, mostly commonly from opioids, now exceed deaths from automobile accidents. There is a significant unmet medical need to provide additional pharmacologic options for treatment of opioid overdose. Emergency medical service personnel would prefer a non- inj ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    ABSTRACT When Cryptococcus is manifested as cryptococcal meningitis (CM), it creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treat. There are now an estimated 2600-7800 US cases and 400,000 cases of CM worldwide annually, with estimated mortality of 15-50% per year. CM is caused when Cryptococcus neoformans, a basidiomycete fungal pathoge ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy

    SBC: Neuro Devices, Inc.            Topic: 107

    DESCRIPTION provided by applicant We devised a new generation highly sensitivity method to diagnosis peripheral neuropathy early when the probability for reversal is greatest Cancer chemotherapy and diabetes are the most common causes of neuropathy in the USA Both cause decreased sweating abnormal circulation peripheral numbness pain and weakness If diagnosed early both are potentially ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Validation of Novel Therapeutic Approach for Leptomeningeal Metastases

    SBC: Minnetronix Medical, Inc.            Topic: 102

    ABSTRACT Leptomeningeal Metastases (LM) is a condition in which tumor cells from a primary tumor metastasize, invade the subarachnoid space (SAS) and spread throughout the cerebrospinal fluid (CSF), resulting in seeding along the meninges, brain and spinal cord. LM represents a devastating event of cancer progression. There are 30,000 cases annually and currently no cure, with average survival of ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Diabetes Insulin Guidance System to Improve Glycemic Control of Diabetic Patients

    SBC: HYGIEIA RESEARCH, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): According to UnitedHealth14 by 2020 half of all Americans would have either diabetes or pre-diabetes with an annual cost of 500 billion - mainly attributed to diabetes related complications. Diabetes is a growing epidemic yet treatment goals are seldom achieved, and patients endure detrimental complications. In the US, 65% of all insulin takers (most of which ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. A nanoparticle delivery system for CRISPR/Cas9 based therapeutics

    SBC: ATGC Inc.            Topic: 100

    Abstract Applications of customizable nucleases such as CRISPRclustered regularly interspaced short palindromic repeatsCasCRISPR associated proteinhave enabled efficient and precise gene correction in vitroand hold promises for eventually achieving in vivo gene correction therapyHoweverto apply CRISPR Casin therapeutic settingsseveral major challenges remain to be addressedihomologous recombinatio ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government